References
- Cirillo I, Mannens G, Janssen C, Vermeir M, Cuyckens F, Desai-Krieger D, Vaccaro N,Kao LM, Devineni D, Redman R, Turner K. (2008). Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. Antimicrob Agents Chemother 52:3478–3483. Epub 2008 Jul 21.
- Harrison MP, Haworth SJ, Moss SR, Wilkinson DM, Featherstone A. (1993). The disposition and metabolic fate of 14C-meropenem in man. Xenobiotica 23:1311–1323.
- Kihara R, Yanagihara K, Morinaga Y, Araki N, Nakamura S, Seki M, Izumikawa K, Kakeya H, Yamamoto Y, Tsukamoto K, Kamihira S, Kohno S. (2008). Potency of SMP-601, a novel carbapenem, in hematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 52:2163–2168.
- King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. (2006). Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 144:309–317.
- Livermore DM, Mushtaq S, Warner M. (2009). Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms. J Antimicrob Chemother 64:330–335.
- Livermore DM, Warner M. (2009). Effects of low temperature and high salt on the activity of the novel carbapenem PZ-601 (SMP-601) against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 63:411–413.
- MacGowan AP, Noel A, Tomaselli S, Elliott H, Bowker K. (2011). Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 55:1436–1442.
- Norrby SR, Björnegård B, Ferber F, Jones KH. (1983). Pharmacokinetics of imipenem in healthy volunteers. J Antimicrob Chemother 12 Suppl D: 109–124.
- Norrby SR, Rogers JD, Ferber F, Jones KH, Zacchei AG, Weidner LL, Demetriades JL, Gravallese DA, Hsieh JY. (1984). Disposition of radiolabeled imipenem and cilastatin in normal human volunteers. Antimicrob Agents Chemother 26:707–714.
- Rhee KY, Gardiner DF, Charles M. (2005). Decreasing in vitro susceptibility of clinical Staphylococcus aureus isolates to vancomycin at the New York Hospital: quantitative testing redux. Clin Infect Dis 40:1705–1706.
- Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC; Infectious Diseases Society of America. (2005). Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 41:1373–1406.
- Tran CM, Tanaka K, Yamagishi Y, Goto T, Mikamo H, Watanabe K. (2011). In vitro antimicrobial activity of razupenem (SMP-601, PTZ601) against anaerobic bacteria. Antimicrob Agents Chemother 55:2398–2402.
- Ueda Y, Kanazawa K, Eguchi K, Takemoto K, Eriguchi Y, Sunagawa M. (2005). In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem. Antimicrob Agents Chemother 49:4185–4196.
- Young C, Rusca A, Di Stefano A, Radicioni M, Binelli D, Xerri L. (2007). Safety and pharmacokinetics of single-dose intravenous administration of PZ-601: a novel investigational carbapenem. Int J Antimicrob Agents 29:S473–S474.